147 related articles for article (PubMed ID: 38669635)
1. High efficacy of CD19 CAR T-cells in patients with transformed Waldenström macroglobulinemia.
Durot E; Roosweil D; Chauchet A; Decroocq J; Di Blasi R; Gastinne T; Bensaber H; Cheminant M; Jacquet C; Guidez S; Gros FX; Bachy E; Coste A; Cony-Makhoul P; Treon SP; Delmer AJ; Reshef R; Le Gouill S; Castillo JJ; Houot R
Blood; 2024 Apr; ():. PubMed ID: 38669635
[TBL] [Abstract][Full Text] [Related]
2. CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience.
Palomba ML; Qualls D; Monette S; Sethi S; Dogan A; Roshal M; Senechal B; Wang X; Rivière I; Sadelain M; Brentjens RJ; Park JH; Smith EL
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35173030
[TBL] [Abstract][Full Text] [Related]
3. Transformed Waldenström Macroglobulinemia Responsive to Tafasitamab Plus Lenalidomide: A Case Report.
Nasir SA; Pandya D; Wojkiewicz S; Khandpur B; Downes E; Pathare P; Frank R
Cureus; 2022 Dec; 14(12):e32403. PubMed ID: 36636536
[TBL] [Abstract][Full Text] [Related]
4. Transformation to diffuse large B-cell lymphoma with germinal center B-cell like subtype and discordant light chain expression in a patient with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Kobayashi H; Asada N; Egusa Y; Ikeda T; Sakamoto M; Abe M; Ennishi D; Sakata M; Takaki A; Kawahara S; Meguri Y; Nishimori H; Fujii N; Matsuoka KI; Sato Y; Yoshino T; Maeda Y
Int J Hematol; 2021 Sep; 114(3):401-407. PubMed ID: 33907976
[TBL] [Abstract][Full Text] [Related]
5. Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
Durot E; Tomowiak C; Michallet AS; Dupuis J; Hivert B; Leprêtre S; Toussaint E; Godet S; Merabet F; Van Den Neste E; Ivanoff S; Roussel X; Zini JM; Regny C; Lemal R; Sutton L; Perrot A; Le Dû K; Kanagaratnam L; Morel P; Leblond V; Delmer A
Br J Haematol; 2017 Nov; 179(3):439-448. PubMed ID: 28770576
[TBL] [Abstract][Full Text] [Related]
6. Clonally related transformation from Waldenström macroglobulinemia to diffuse large B-cell lymphoma with central nervous system involvement at diagnosis: a case report and literature review.
Chen H; Zhao D; Wang Z; Zhang W; Wang W
Clin Exp Med; 2023 Dec; 23(8):5473-5476. PubMed ID: 37921873
[TBL] [Abstract][Full Text] [Related]
7. Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenström macroglobulinemia.
Sun H; Fang T; Wang T; Yu Z; Gong L; Wei X; Wang H; He Y; Liu L; Yan Y; Sui W; Xu Y; Yi S; Qiu L; Hao M
J Transl Med; 2022 Dec; 20(1):576. PubMed ID: 36494694
[TBL] [Abstract][Full Text] [Related]
8. Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with
Zhu J; Zhu X; Xie F; Ding Y; Lu H; Dong Y; Li P; Fu J; Liang A; Zeng Y; Xiu B
Pathol Oncol Res; 2023; 29():1611070. PubMed ID: 37151353
[No Abstract] [Full Text] [Related]
9. A prognostic index predicting survival in transformed Waldenström macroglobulinemia.
Durot E; Kanagaratnam L; Zanwar S; Kastritis E; D'Sa S; Garcia-Sanz R; Tomowiak C; Hivert B; Toussaint E; Protin C; Abeykoon JP; Guerrero-Garcia T; Itchaki G; Vos JM; Michallet AS; Godet S; Dupuis J; Leprêtre S; Bomsztyk J; Morel P; Leblond V; Treon SP; Dimopoulos MA; Kapoor P; Delmer A; Castillo JJ
Haematologica; 2021 Nov; 106(11):2940-2946. PubMed ID: 33179472
[TBL] [Abstract][Full Text] [Related]
10. Evaluation and Management of Disease Transformation in Waldenström Macroglobulinemia.
Talaulikar D; Tomowiak C; Toussaint E; Morel P; Kapoor P; Castillo JJ; Delmer A; Durot E
Hematol Oncol Clin North Am; 2023 Aug; 37(4):787-799. PubMed ID: 37246087
[TBL] [Abstract][Full Text] [Related]
11. Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia.
Castillo JJ; Gustine J; Meid K; Dubeau T; Hunter ZR; Treon SP
Am J Hematol; 2016 Oct; 91(10):1032-5. PubMed ID: 27415417
[TBL] [Abstract][Full Text] [Related]
12. Impact of MYD88
Zanwar S; Abeykoon JP; Durot E; King R; Perez Burbano GE; Kumar S; Gertz MA; Quinquenel A; Delmer A; Gonsalves W; Cornillet-Lefebvre P; He R; Warsame R; Buadi FK; Novak AJ; Greipp PT; Inwards D; Habermann TM; Micallef I; Go R; Muchtar E; Kourelis T; Dispenzieri A; Lacy MQ; Dingli D; Nowakowski G; Thompson CA; Johnston P; Thanarajasingam G; Bennani NN; Witzig TE; Villasboas J; Leung N; Lin Y; Kyle RA; Rajkumar SV; Ansell SM; Le-Rademacher JG; Kapoor P
Am J Hematol; 2020 Mar; 95(3):274-281. PubMed ID: 31814157
[TBL] [Abstract][Full Text] [Related]
13. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
Leleu X; Soumerai J; Roccaro A; Hatjiharissi E; Hunter ZR; Manning R; Ciccarelli BT; Sacco A; Ioakimidis L; Adamia S; Moreau AS; Patterson CJ; Ghobrial IM; Treon SP
J Clin Oncol; 2009 Jan; 27(2):250-5. PubMed ID: 19064987
[TBL] [Abstract][Full Text] [Related]
14. High plasma D-dimer level is a poor prognostic factor for patients with waldenström macroglobulinemia.
Cao X; Kong YL; Wang L; Zhu HY; Liang JH; Xia Y; Fan L; Shi WY; Liu H; Li JY; Xu W
Leuk Lymphoma; 2020 May; 61(5):1140-1146. PubMed ID: 31928271
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous Waldenstrom macroglobulinemia in transformation.
Appenzeller P; Leith CP; Foucar K; Scott AA; Bigler CF; Thompson CT
Am J Dermatopathol; 1999 Apr; 21(2):151-5. PubMed ID: 10218675
[TBL] [Abstract][Full Text] [Related]
16. Clinical, Laboratory, and Bone Marrow Findings of 31 Patients With Waldenström Macroglobulinemia.
Ahn A; Park CJ; Cho YU; Jang S; Seo EJ; Lee JH; Yoon DH; Suh C
Ann Lab Med; 2020 May; 40(3):193-200. PubMed ID: 31858758
[TBL] [Abstract][Full Text] [Related]
17. Real-world data on the survival outcome of patients with newly diagnosed Waldenström macroglobulinemia.
Cho JH; Shim JH; Yoon SE; Kim HJ; Kim SH; Ko YH; Lee ST; Kim K; Kim WS; Kim SJ
Korean J Intern Med; 2021 May; 36(3):668-678. PubMed ID: 32791817
[TBL] [Abstract][Full Text] [Related]
18. The epidemiology of Waldenström macroglobulinemia.
McMaster ML
Semin Hematol; 2023 Mar; 60(2):65-72. PubMed ID: 37099032
[TBL] [Abstract][Full Text] [Related]
19. Case report: A rare case of coexisting Waldenstrom Macroglobulinemia and B-cell acute lymphoblastic leukemia with KMT2D and MECOM mutations.
Wang L; Tang J; Feng J; Huang Y; Cheng Y; Xu H; Miao Y
Front Immunol; 2022; 13():1001482. PubMed ID: 36325357
[TBL] [Abstract][Full Text] [Related]
20. Microarray-Based Gene Expression Analysis Identifies Potential Diagnostic and Prognostic Biomarkers for Waldenström Macroglobulinemia.
Xu H; Yao F
Acta Haematol; 2018; 140(2):87-96. PubMed ID: 30227405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
